Zevra Therapeutics Inc expected to post earnings of $1.50 a share - Earnings Preview

Zevra Therapeutics

08/08/2025 22:29

Zevra Therapeutics Inc ZVRA.OQ ZVRA.O is expected to  show a rise in quarterly revenue when it reports  results on August 12 for the period ending June 30 2025

The Celebration Florida-based  company is expected to report a 406.5% increase in revenue to $22.535 million from $4.45 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Zevra Therapeutics Inc is for earnings of $1.50 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Zevra Therapeutics Inc is $25.00, about 51.5% above its last closing price of $12.13

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.19
-0.19
-0.06
Beat
67.9
Dec. 31 2025
-0.40
-0.40
-0.69
Missed
-70.7
Sep. 30 2024
-0.42
-0.42
-0.69
Missed
-63.8​
Jun. 30 2024
-0.44
-0.43
-0.48
Missed
-10.6
​​Mar. 31 2024
-0.48
-0.48
-0.40
Beat
16.3
Dec. 31 2023
-0.19
-0.27
-0.40
Missed
-49.1​
Sep. 30 2023
-0.30
-0.30
-0.40
Missed
-34.5
Jun. 30 2023
-0.37
-0.34
-0.15
Beat
56.3

This summary was machine generated August 8 at 21:29 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)